(3) PBMCs from CML patients showed lower SAMHD1 phosphorylation after PHA/IL-2 treatment for five days (p < 0.0001 for dasatinib; p < 0.01 for bosutinib). This evidence concerns the gene IL2 and chronic myelogenous leukemia, BCR-ABL1 positive.